Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.
Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.
Small molecule and pharmaceutical IP is about more than the compound. Formulations, dosing regimens, new indications and life cycle planning all add protection, and each has to work in every major market.
Antibody IP is shaped by very different rules in the US, Europe, Japan and China, and by competition from biosimilars and fast followers. ADCs and T cell engagers add further layers of binders, linkers, payloads and formats.
A cell or gene therapy is an assembly of separately owned parts: binders, vectors, delivery systems, engineered cells and manufacturing processes. We help you protect what is yours in each, clear what is not, and build an estate that supports the deal.
AI drug discovery companies need strong patents on the medicines they discover, and a clear view of what to patent and what to keep secret about the platform, the models and the data behind it.